Impact of the Clinical Trials Act 2018 on clinical trial activity in Japan from 2018 to 2020: a retrospective database study using new and conventional Japanese registries

Author:

Taruno HiroyukiORCID,Oba Mari SORCID,Takizawa Osamu,Kikuchi Kayoko,Matsui Kazuaki,Shikano MayumiORCID

Abstract

ObjectiveTo clarify the impact of Japan’s Clinical Trials Act (CTA), which was enacted in April 2018, on subsequent clinical trial activity through an analysis of Japanese registry data.DesignRetrospective database study.SettingWe extracted information on clinical intervention studies registered between 1 April 2018 and 30 September 2020 in the conventional University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) and the new Japan Registry of Clinical Trials (jRCT). We collected and analysed information on registration dates, intervention types, funding, secondary sponsors and use of designated staff in multidisciplinary roles (research planning support, research administration, data management, statistical analysis, monitoring and auditing). The temporal trends in clinical trial activity after CTA enactment were examined.ResultsA total of 577 CTA-compliant specified clinical trials (ie, studies funded by pharmaceutical companies or studies evaluating the efficacy and safety of off-label drugs or devices in humans) were registered in the jRCT. During the same period, 5068 clinical trials were registered in the UMIN-CTR. The number of specific clinical trials increased immediately after the implementation of the CTA and stabilised in late 2019, whereas the number of clinical trials registered in the UMIN-CTR generally declined over time. Specified clinical trials that received industry funding and public grants were more likely to use designated staff in multidisciplinary roles.ConclusionsThe implementation of the CTA has not reduced the number of specified clinical trials, but has reduced the total number of intervention trials. The use of designated staff in multidisciplinary roles is associated with funding, secondary sponsors and multicentre studies. It was inferred that funding was needed to establish research infrastructure systems that support high-quality research.

Publisher

BMJ

Subject

General Medicine

Reference16 articles.

1. U.S. Department of Health & Human Services . Final rule delaying general compliance of revised common rule, 2018. Available: https://www.hhs.gov/ohrp/final-rule-delaying-general-compliance-revised-common-rule.html [Accessed 9 Oct 2021].

2. The historical, ethical, and legal background of human-subjects research;Rice;Respir Care,2008

3. Reformation of clinical trial regulations in European Union (EU);Kurihara;Rinsyo Hyoka/Clinical Eval,2014

4. For life sciences and medical research involving human subjects ethical guideline. Available: https://www.lifescience.mext.go.jp/files/pdf/n2312_01.pdf

5. Law on securing quality, efficacy and safety of pharmaceuticals, medical devices, regenerative and cellular therapy puroducts, gene therapy products, and cosmetics, 2015. Available: https://www.jiho.co.jp/Portals/0/ec/product/ebooks/book/47578/47578.pdf

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3